Nuvation Bio (NUVB) Total Current Liabilities (2020 - 2026)

Nuvation Bio (NUVB) has reported Total Current Liabilities for 7 consecutive years, with $79.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities rose 50.69% year-over-year to $79.5 million; the TTM figure through Mar 2026 stood at $79.5 million (up 50.69% YoY), while the FY2025 annual figure was $82.2 million, up 41.18% from the prior year.
• Total Current Liabilities eased to $79.5 million in Q1 2026 per NUVB's latest filing, from $82.2 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $82.2 million in Q4 2025 and bottomed at $12.6 million in Q1 2023.
• Historically, Total Current Liabilities has averaged $38.8 million across 5 years, with a median of $21.4 million in 2022.
• Annual changes were most pronounced in 2023 — Total Current Liabilities sank 41.46% — and 2024, when it surged 316.8%.
• Nuvation Bio's Total Current Liabilities stood at $13.2 million in 2022, then rose by 6.18% to $14.0 million in 2023, then jumped by 316.8% to $58.2 million in 2024, then surged by 41.18% to $82.2 million in 2025, then declined by 3.29% to $79.5 million in 2026.
• Business Quant data shows NUVB's Total Current Liabilities at $79.5 million in Q1 2026, $82.2 million in Q4 2025, and $68.1 million in Q3 2025.